In the claims:

Please cancel claims 9 and 12-14. Please amend the claims as follows:

1. **(Currently Amended)** A ~~non-photoreactive~~ targeted oligonucleotide construct comprising: a targeting moiety which localizes to a site in an organism; an oligonucleotide complementary to a nucleic acid of interest; and ~~a detectable label~~an imaging agent suitable for use in Positron Emission Tomography (PET), Single Photon Emission Tomography (SPECT) or Magnetic Resonance Imaging (MRI), ~~wherein said construct is not encapsulated in a liposome or linked to a lipid and wherein said construct does not comprise a receptor-binding internalized ligand~~ wherein the targeting moiety is selected from an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, a small molecule and a protein.

2. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein ~~the targeting moiety~~said imaging agent is selected from the group consisting of: an unpaired spin atom, a free radical, a paramagnetic contrast agent and a metal chelate ~~a lipid, an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, and a protein~~.

3. **(CurrentlyAmended)** A targeted oligonucleotide construct as in claim 1, wherein ~~the detectable label~~said imaging agent is a paramagnetic contrast agent selected from the group consisting of: ~~a chemiluminescent label, a radioisotope, a fluorescent label, a paramagnetic contrast agent, and a metal chelate~~gadolinium, cobalt, nickel, manganese, and iron.

4. **(Previously Presented)** A targeted oligonucleotide construct as in claim 1, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.

5. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein ~~the detectable label and the targeting moiety are each coupled to the oligonucleotide in any configuration that maintains the desired activity of said label and said moiety~~said imaging agent is a radiolabel selected from the group consisting of: ^{131}I, ^{123}I, ^{99m}Tc, ^{18}F, ^{68}Ga, ^{67}Ga, ^{72}As, ^{89}Zr, ^{64}Cu, ^{62}Cu, ^{111}In, ^{203}Pb, ^{198}Hg, ^{11}C, ^{97}Ru, and ^{201}Tl.

6. **(Currently Amended)** A targeted oligonucleotide construct as in claim ~~1~~5, wherein the ~~oligonucleotide and the detectable label are each coupled to the~~

~~targeting moiety in any configuration that maintains the desired activity of said label and said moiety~~radiolabel is a chelate.

7. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein ~~the targeting moiety and the oligonucleotide are each coupled to the detectable label in any configuration that maintains the desired activity of said label and said moiety~~said imaging agent is an iron, lanthanide or gadolinium unpaired spin atom or free radical.

8. **(Currently Amended)** ~~A non-photoreactive targeted oligonucleotide conjugate comprising: a targeting moiety which localizes to a site in an organism; an oligonucleotide complementary to a nucleic acid of interest, and a therapeutic agent, wherein said construct is not encapsulated in a liposome or linked to a lipid and wherein said construct does not comprise a receptor-binding internalized ligand~~A targeted oligonucleotide construct as in claim 1, further comprising a therapeutic agent.

9. **(Cancelled)** ~~A targeted oligonucleotide construct as in claim 1, wherein the targeting moiety is selected from a lipid, a lectin, a sugar, a steroid, a hormone, a nutrient, and a small molecule.~~

10. **(Previously Presented)** A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent is selected from an enzyme, an enzyme inhibitor, a receptor ligand, a radioisotope, an antibiotic, a steroid, a hormone, a polypeptide, a glycopeptide, a phospholipid, and a drug.

11. **(Previously Presented)** A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.

12. **(Cancelled)** ~~A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent and the targeting moiety are each coupled to the oligonucleotide in any configuration that maintains the desired activity of said therapeutic agent and said moiety.~~

13. **(Cancelled)** ~~A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide and the therapeutic agent are each coupled to the targeting moiety in any configuration that maintains the desired activity of said therapeutic agent and said moiety.~~

14. **(Cancelled)** ~~A targeted oligonucleotide construct as in claim 8, wherein the targeting moiety and the oligonucleotide are each coupled to the therapeutic agent in any configuration that maintains the desired activity of said label therapeutic agent and said moiety.~~

Claims 15-24 **(Cancelled)**

25. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a cell uptake facilitating moiety, an antisense oligonucleotide that is modified with a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.

26. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.

27. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate moiety.

28. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.

29. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to a gene selected from the group consisting of : C-myb, N-myc, C-myc and PSA gene specific antisense.

30. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a cell uptake facilitating moiety, an antisense oligonucleotide that is modified with

a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.

31. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.

32. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate group.

33. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to a gene selected from the group consisting of : C-myb, N-myc, C-myc and PSA gene specific antisense.

34. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.